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Objective: Patients who present for carotid endarterectomy (CEA) with symptoms of stroke or transient ischemic attack
(TIA) have worse postoperative outcomes than patients with asymptomatic carotid disease. We undertook this study to
see whether preoperative medication use or patient characteristics were associated with the presence of symptomatic
cerebrovascular disease at the time of operation.
Methods: A retrospective case-control study was performed among patients presenting for elective CEA at a single
academic institution between 1994 and 2004. A total of 660 (42%) symptomatic patients were identified from an
institutional database and compared with 901 (58%) control patients who were asymptomatic at the time of CEA. The
independent association of cerebrovascular symptoms with patient variables was assessed by using multivariate logistic
regression analysis after propensity score adjustment.
Results: The mean age and sex distribution were similar between cases and controls, although symptomatic patients were
more likely to have an ulcerative plaque (18% symptomatic vs 11% asymptomatic; P< .01). Compared with asymptomatic
controls, patients presenting for CEA with symptoms of stroke or TIA were less likely to have hyperlipidemia (43% vs
55%; P< .01) or a history of coronary artery disease (43% vs 54%; P< .01) and were less likely to be receiving statins (35%
vs 47%; P < .01), -blockers (34% vs 44%; P < .01), and diuretics (22% vs 31%; P < .01). After controlling for potential
interaction and confounding by using propensity score adjustment and logistic regression analysis, preoperative use of
statins (adjusted odds ratio, 0.72; 95% confidence interval, 0.56-0.92; P  .01) and diuretics (adjusted odds ratio, 0.74;
95% confidence interval, 0.58-0.95; P  .02) were independently associated with a lower likelihood of having
cerebrovascular symptoms at the time of CEA.
Conclusions:We observed that patients receiving statins or diuretics were less likely to present for CEA with symptoms of
stroke or TIA. These data raise the question of whether the preoperative use of these medications protects patients with
carotid stenosis from developing symptomatic disease and contributes to improved outcomes among patients undergoing
CEA. Further research is needed to assess the optimal medical management of patients before vascular surgery. (J Vasc
Surg 2007;45:298-303.)Carotid endarterectomy (CEA) is the most frequently
performed peripheral vascular operation in this country and
remains the gold standard treatment for carotid atheroscle-
rotic disease.1,2 Clinical indications for CEA are based on
the degree of carotid artery stenosis and the presence of
neurologic symptoms related to carotid atherosclerotic dis-
ease. This includes symptoms associated with stroke, tran-
sient ischemic attack (TIA), and amaurosis fugax. Numer-
ous randomized clinical trials have proven that CEA is
effective for patients presenting with both symptomatic and
asymptomatic carotid disease.3-5 These studies have also
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298established that the presence of cerebrovascular symptoms
at the time of operation is associated with a higher rate of
adverse perioperative outcomes, including stroke and mor-
tality.
Epidemiologic studies have identified multiple risk fac-
tors for the development of carotid artery disease. Among
patients with moderate to high-grade carotid stenosis re-
ferred for CEA, however, it is unclear what specific factors
predict the development of clinical symptoms and neuro-
logic sequelae. It has been speculated that inadequate med-
ical management of hypertension is a critical risk factor that
contributes to both the development of carotid stenosis
and the progression of cerebrovascular symptoms.6 Recent
data also suggest that the composition of carotid athero-
sclerotic plaques is highly correlated with clinical manifes-
tations.7,8 Specifically, high levels of inflammatory cells,
cytokines, and proteases within plaques are associated with
instability and the development of adverse cerebrovascular
events during the perioperative period.
There has been a lot of debate regarding the appropri-
ate pharmacologic management to treat and prevent ca-
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show conflicting results regarding the efficacy of different
antihypertensive medications for the prevention of stroke.9,10
Moreover, although the exact relationship between hyper-
cholesterolemia and cerebrovascular disease is unclear, nu-
merous randomized clinical trials have demonstrated that
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibi-
tors (statins) reduce the risk of stroke in high-risk medical
patients.11,12 It is thought that the reduction of inflamma-
tory mediators by the non–lipid-related pleiotropic effects
of statins may help alter the composition of and stabilize
carotid plaques.13
The incidence of perioperative strokes and TIAs among
patients undergoing CEA may be reduced by providing
optimal pharmacologic agents that target risk factors before
surgery. However, there has been a lot of debate regarding
the appropriate preoperative management of carotid artery
disease, and no study to date, to our knowledge, has
evaluated whether specific pharmacologic agents reduce
the incidence of clinical symptoms among patients with
moderate to high-grade stenosis. To address this question,
we examined whether commonly used cardiovascular agents
were associated with a reduction in symptomatic carotid dis-
ease among patients presenting for CEA at a large academic
institution. Decreasing the presentation of carotid artery
stenosis from symptomatic to asymptomatic may reduce
patient risk and improve CEA outcomes.
METHODS
Study patients. All patients undergoing CEA at the
Johns Hopkins Hospital in Baltimore, Md, between 1994
and 2004 were identified from an institutional database.
Permission to review patient records was granted by the
institutional review board. Cases were identified by review-
ing the medical history of each patient who presented for
CEA during the time period and finding documentation of
recent symptoms attributed to ipsilateral carotid stenosis,
including evidence of stroke, TIA, or amaurosis fugax. This
classification was made on the basis of clinical history and
supported by radiographic evidence (when available).
Asymptomatic controls were selected at a 1.5:1 ratio from
age-matched patients who presented for CEA within the
same month of surgery without any clinical symptoms of
cerebrovascular disease.
Study variables. The exposure variables for this
analysis included recent medication use of 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors (statins),
-blockers, diuretics, angiotensin-converting enzyme in-
hibitors, and calcium channel blockers. Other medical
classes, including antiplatelet therapies, were not studied as
a result of insufficient data. Diuretics were defined to
include both the thiazide and loop-diuretic classifications,
whereas calcium channel blockers included both the dihy-
dropyridine and benzothiazepine classes. Patients were
documented to be taking these medications for chronic
medical conditions at their preoperative clinic visit, which
was usually 2 to 4 weeks before surgery. The dose was
collected for each medication, although the exact durationof therapy was unknown. All other patient characteristics
that might be associated with cerebrovascular symptoms
were analyzed, including demographic characteristics (age,
sex, and race), plaque characteristics (presence of ulceration
and degree of stenosis in the ipsilateral and contralateral
carotid arteries), and other cardiovascular comorbidities
(history of coronary disease, history of coronary revascular-
ization, history of myocardial infarction, history of atrial
fibrillation, chronic renal insufficiency, history of smoking,
diabetes mellitus, and hyperlipidemia). A complete list of
patient variables assessed can be seen in Table I. The
identification of all patient comorbidities, including hyper-
lipidemia, hypertension, and diabetes, was made after re-
viewing each patient’s medical records, which detailed the
results of previous physical examinations and laboratory
results. The determination of the mean percentage of ste-
nosis in ipsilateral and contralateral carotid arteries was
made by reviewing all preoperative imaging studies that
used duplex ultrasonography, carotid angiography, or
Table I. Baseline characteristics of patients presenting for
carotid endarterectomy by the presence of
cerebrovascular symptoms
Variable
Symptomatic
(n  660; 42%)
Asymptomatic
(n  901; 58%)P value
Age, y (mean  SD) 72.4  10.6 72.0  9.3 .50
Male 428 (65%) 556 (62%) .32
White 585 (89%) 818 (91%) .28
Black 68 (10%) 74 (8%) .16
Right-sided lesion 330 (50%) 436 (48%) .68
Ulcerative plaque 116 (18%) 99 (11%) .01*
Ipsilateral % stenosis
(mean  SE) 84.7  11.6 85.8  9.1 .04*
Contralateral stenosis 116 (18%) 170 (19%) .51
Diabetes mellitus 175 (27%) 231 (26%) .70
Hypertension 514 (78%) 730 (81%) .13
Current A-Fib 26 (4%) 47 (5%) .24
CHF 51 (8%) 77 (9%) .56
Hyperlipidemia 283 (43%) 491 (55%) .01*
History of CAD 281 (43%) 483 (54%) .01*
History of MI 111 (17%) 185 (21%) .06*
History of CABG 105 (16%) 163 (18%) .26
History of smoking 119 (18%) 236 (26%) .01*
CRI 31 (5%) 57 (6%) .17
Statin 228 (35%) 426 (47%) .01*
ACE inhibitor 158 (24%) 233 (26%) .39
Calcium channel blocker 181 (27%) 240 (27%) .73
-Blocker 227 (34%) 400 (44%) .01*
Diuretic 146 (22%) 278 (31%) .01*
Preoperative creat
(mean  SE) (mg/dL) 1.37  0.25 1.31  0.13 .84
Synch. CEA/CABG 17 (3%) 109 (12%) .01*
CHF, Congestive heart failure; A-fib, atrial fibrillation; CAD, coronary
artery disease; MI, myocardial infarction; CABG, coronary artery bypass
grafting; CRI, chronic renal insufficiency; ACE, angiotensin converting
enzyme; creat, creatinine; Synch. CEA/CABG, synchronous carotid endar-
terectomy and coronary artery bypass procedure.
Differences between patients presenting for CEA with symptomatic and
asymptomatic carotid disease were compared by using the Student t test for
continuous variables and the 2 test for categorical data.
*P  .05.magnetic resonance angiography.
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formed by using Stata statistical software, version 9.1 (Stata
Corp, College Station, Tex). Differences between patients
presenting for CEA with symptomatic and asymptomatic
carotid disease were compared by using the Student t test or
the Wilcoxon rank sum test for continuous variables and
the 2 or Fisher exact test for categorical data. Variables
were selected for multiple logistic regression analysis if they
differed between groups on bivariate analysis at a P value
(two sided) .1 or if they were selected by forward and
backward stepwise regression at the same significance level.
The presence of interactions among predictor variables was
assessed by using nested models and the likelihood ratio
test. All interaction variables found to be statistically signif-
icant (P  .05) were stratified by quartile to examine the
strength of their effect on symptomatic status. Odds ratios
(ORs) were used as the measure of association in the final
multiple logistic regression model.
Propensity scores were calculated for the probability
that patients would receive pharmacologic therapy with
statins, -blockers, and diuretics by using all patient char-
acteristics within a logistic regression model. The propen-
sity score represents the probability (between 0% and
100%) of receiving a given medication rather than no
medication, on the basis of observed baseline characteris-
tics.14 Patient characteristics associated with either a higher
or lower probability to be treated (P  .05) with a given
medication were determined and used to determine the
final propensity score model. These propensity scores were
included in the final logistic regression model, along with
medications and interaction terms, where appropriate. The
model fit was assessed by using the Hosmer-Lemeshow
goodness-of-fit method, and discrimination was assessed by
using receiver operating characteristic (ROC) methods.
The ROC can be defined as the ability of a model to
differentiate between two possible outcomes and is re-
ported by the area under the curve value, ranging from 0.5
(no better than chance) to 1.0 (complete success). P values
.05 were considered to be statistically significant for the
final model.
RESULTS
Patient population and baseline characteristics. A
total of 1561 patients presented for CEA at the Johns
Hopkins Hospital between 1994 and 2004, including 126
patients who underwent CEA before synchronous coro-
nary artery bypass grafting (CABG) surgery. All patients
identified during this time period were included in the final
analysis. This included 660 (42%) patients who had docu-
mented symptoms of stroke or TIA at the time of CEA and
991 (58%) patients without any clinical symptoms (Table I).
Among the patients with clinical symptoms, 226 (34%)
were certified by a neurologist to have evidence of a stroke,
whereas the remaining 434 (66%) patients were docu-
mented to have evidence of TIA. The mean age and distri-
bution of sex and race did not differ statistically between
symptomatic and asymptomatic groups. Patients present-
ing with symptoms were more likely to have evidence ofcarotid plaque ulceration (18% vs 11%; P .01) and a lower
mean percentage of ipsilateral carotid stenosis than asymp-
tomatic patients. When stenosis was stratified by quintile,
patients presenting with symptoms weremore likely to have
ipsilateral carotid stenosis between 50% and 80% (21% vs
13%; P .01), compared with asymptomatic patients, who
were more likely to have carotid disease between 80% and
90% (29% vs 24%; P  .02). Patients who presented for
CEA with symptoms of stroke or TIA were also less likely
than asymptomatic patients to present before a synchro-
nous CABG procedure (3% vs 12%; P  .01) or to have a
history of hyperlipidemia (42% vs 55%; P  .01), coronary
disease (43% vs 54%; P .01), and smoking (18% vs 26%;
P  .01).
Medication use and symptomatic disease presentation.
At the time of operation, 1172 (75%) patients were taking
at least 1 cardiovascular medication, which included the use
of a statin, -blocker, calcium channel blocker, diuretic, or
angiotensin-converting enzyme inhibitor. There were 657
(42%) patients taking a 3-hydroxy-3-methylglutaryl coen-
zyme A reductase inhibitor (statin) drug, 627 (40%) patients
taking a -blocker, 424 (27%) patients taking a diuretic, 391
(25%) patients taking an angiotensin-converting enzyme in-
hibitor, and 421 (27%) patients taking a calcium channel
blocker. When stratified in bivariate analysis, patients with
symptomatic carotid disease were less likely than asymp-
tomatic patients to be taking a statin (35% vs 47%; P .01),
-blocker (34% vs 44%; P  .01), or diuretic medication
(22% vs 31%; P  .01) at the time of CEA. In comparison,
there were no statistically significant differences between
groups in the use of calcium channel blockers or angiotensin-
converting enzyme inhibitor medications at the time of
CEA.
Propensity for statin, -blocker, and diuretic
therapy. The propensity score represents the probability
of a patient receiving treatment with any given medication
(vs no treatment) on the basis of observed baseline comor-
bidities and characteristics.14 Propensity scores were g e n -
erated for the medications in this study found to be
statistically significant between groups in bivariate anal-
ysis. Patients had a higher propensity to be receiving
statin therapy with hyperlipidemia (OR, 8.99; 95% confi-
dence interval [CI], 7.0-11.6) andmale sex (OR, 1.32; 95%
CI, 1.0-1.7), whereas the propensity decreased with in-
creasing age (OR, 0.96; 95% CI, 0.95-0.98) and chronic
renal insufficiency (OR, 0.42; 95% CI, 0.24-0.74). The
propensity for statin therapy was also higher for patients
concurrently taking -blockers (OR, 1.92; 95% CI,
1.48-2.50), diuretics (OR, 1.49; 95% CI, 1.13-1.98),
and angiotensin-converting enzyme inhibitors (OR, 1.34;
95% CI, 1.01-1.79). The area under the ROC curve for the
multivariate model predicting statin use was 0.81.
Patients had a higher propensity to receiving -blocker
therapy with a history of myocardial infarction (OR, 1.94;
95% CI, 1.43-2.64), coronary disease (OR, 1.54; 95% CI,
1.18-2.01), and hypertension (OR, 3.18; 95% CI, 2.27-4.46).
Patients had a lower propensity for -blocker use with
increasing age (OR, 0.98; 95%CI, 0.97-0.99) and smoking
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-blocker therapy was also increased for patients concur-
rently taking statins (OR, 1.94; 95% CI, 1.50-2.52) and
diuretics (OR, 1.39; 95% CI, 1.09-1.78). The area under
the ROC curve for the multivariate model predicting
-blocker use was 0.68.
The propensity for diuretic use was higher in patients
with a history of coronary disease (OR, 1.70; 95% CI,
1.28-2.28), hypertension (OR, 2.98; 95% CI, 1.96-4.54),
and smoking (OR, 1.43; 95% CI, 1.08-1.88), as well as
those patients concurrently taking -blockers (OR, 1.42;
95% CI, 1.11-1.82), statins (OR, 1.48; 95% CI, 1.12-
1.96), angiotensin-converting enzyme inhibitors (OR,
1.47; 95% CI, 1.13-1.90), and calcium channel blockers
(OR, 1.43; 95% CI, 1.10-1.84). The area under the
ROC curve for the multivariate model predicting di-
uretic use was 0.68.
Multivariate association of medication use with
symptomatic carotid disease. The association between
cardiovascular medication use and the likelihood of pre-
senting for CEA with symptomatic carotid disease was
evaluated by using multivariate logistic regression analysis
with propensity score adjustment. After controlling for
potential interaction and confounding, statin (adjusted
OR, 0.72; 95% CI, 0.55-0.91) and diuretic (adjusted OR,
0.74; 95% CI, 0.58-0.94) medications were both indepen-
dently associated with a lower likelihood of presenting with
cerebrovascular symptoms at the time of CEA (Fig and
Table II). In comparison, no statistically significant effect
Fig. Multivariate associations between preoperative medication
use and odds of presenting with symptoms of stroke or transient
ischemic attack among patients with moderate to high-grade ca-
rotid artery stenosis. Point estimates with 95% confidence intervals
(CIs) are shown on a logarithmic scale. ACE, Angiotensin-
converting enzyme.was found for calcium channel blockers or angiotensin-converting enzyme inhibitors. A statistically significant quali-
tative interaction effect was found between -blockers and
-blocker propensity for the presence of symptomatic dis-
ease (P  .05). After -blocker propensity was stratified
into quartiles, the association between -blockers and
symptoms at presentation for CEA was found to have a
wide CI that was not statistically significant (adjusted OR,
1.70; 95% CI, 0.72-4.03; Fig and Table II). The area under
the ROC curve for this final multivariate model predicting
symptoms at presentation for CEA was 0.63. This model
was found to adequately represent the data by Hosmer-
Lemeshow goodness-of-fit analysis (P  .15).
DISCUSSION
Patients presenting for CEA with symptomatic carotid
artery disease are known to have a higher rate of perioper-
ative complications than patients without symptoms at the
time of operation.1-5 This includes an increased risk for
postoperative stroke and mortality. Reducing the presence
of symptoms among patients with moderate to high-grade
carotid stenosis may therefore help to reduce the incidence
of these adverse outcomes after CEA. Our data suggest that
preoperative statin and diuretic therapy significantly re-
duces the likelihood that patients will present with symp-
tomatic carotid artery disease. After propensity score ad-
justment, both of these medications were independently
associated with a greater than 25% reduction in clinical
symptoms at the time of operation.
The mechanism of stroke in patients with carotid artery
disease has been elucidated with the aid of numerous in
vitro and in vivo studies over the past couple of decades.
Although some strokes associated with carotid stenosis
may be related to hypoperfusion, most seem to result
from the embolization of unstable atherosclerotic ca-
rotid plaques.7,13 There have been several studies that have
compared carotid atherosclerotic plaques from symptom-
atic and asymptomatic patients in an attempt to elucidate
the mechanisms underlying plaque rupture and emboliza-
Table II. Final multivariate model with adjusted
odds for all variables associated with presenting
with symptomatic carotid disease at the time of
carotid endarterectomy
Variable
Adjusted OR
(95% CI) P value
Statin medication use 0.72 (0.56-0.92) .01
Diuretic medication use 0.74 (0.58-0.95) .02
-Blocker medication use 1.70 (0.72-4.03) .23
Calcium channel blocker
medication use 1.30 (0.99-1.71) .06
ACE inhibitor medication use 1.25 (0.93-1.67) .14
Black 1.31 (0.91-1.89) .14
Ipsilateral carotid stenosis 50%-80% 1.69 (1.27-2.25) .01
Ulcerative plaque 1.47 (1.08-1.98) .01
OR, Odds ratio; CI, confidence interval; ACE, angiotensin-converting
enzyme.tion.15-17 In patients with similar degrees of stenosis, the
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that contain more inflammatory cells, cytokines, and pro-
teases, as well as a thinner fibrous cap.17,18 One study also
found that the quantity of extractable lipids was greater in
symptomatic plaques.19
The significant reduction in symptomatic carotid dis-
ease associated with statin therapy in this study supports the
growing body of evidence demonstrating a neuroprotective
benefit for these medications. Numerous randomized clin-
ical trials in high-risk medical patients have clearly demon-
strated that statin drugs are highly effective in primary and
secondary stroke prevention.11,20 These results have also
been demonstrated in patients with normal lipid levels, thus
suggesting that some degree of statins’ neuroprotective
benefit may be independent of lipid lowering. The non–
lipid-mediated, or pleiotropic, functions of statins include
diverse cellular effects, including the suppression of numer-
ous inflammatory processes that are known to degrade the
extracellular matrix and lead to plaque disruption.21,22
Pathologic analyses of carotid plaques taken from patients
after CEA had significantly lower levels of inflammatory
mediators such as macrophages, cytokines, and matrix met-
alloproteinases if they were taking a statin medication be-
fore surgery.22,23 Thus, statins’ anti-inflammatory effects
seem to stabilize carotid plaques that would otherwise be
disrupted, embolize, and lead to postoperative strokes. A
recent study by our group supports this theory by showing
that perioperative statin use during CEAwas independently
associated with a significant reduction in the incidence of
30-day stroke, TIA, and mortality among patients with
both symptomatic and asymptomatic presentations.24 This
work was confirmed by a second independent study that
showed a reduction in the combined outcome of stroke or
death associated with statin therapy, although, interest-
ingly, only patients with symptomatic carotid disease at the
time of CEA received this benefit.25
Hypertension is a known risk factor for the develop-
ment of cerebrovascular disease, including stroke and TIA,
although the choice of optical medical management has not
always been clear. Our data agree with the results of several
large clinical trials suggesting that diuretic therapy may
confer an additional benefit over other antihypertensive
medications in reducing the risk of stroke.26,27 In a large
meta-analysis including more than 48,000 patients, high-
dose diuretic therapy was found to reduce the risk of stroke
by 51%, compared with a 29% reduction with the use of
-blockers.28 Another study found that among patients
with no history of coronary artery disease being treated for
essential hypertension, the adjusted risk of ischemic stroke
was 2 to 2.5 times higher among users of -blockers,
calcium channel blockers, and angiotensin-converting
enzyme inhibitors than among patients receiving di-
uretic therapy.10 The mechanism of this additional cere-
broprotective benefit by diuretics has been speculated to
derive from activation of the renin-angiotensin system
a n d increased angiotensin II levels.29 Specifically, the non–
angiotensin I receptors are upregulated in the brain after
global ischemia and may serve as mediators of cerebropro-tection by recruiting collateral circulation and decreasing
neuronal apoptosis.
Ensuring that patients are receiving optimal medical
therapy before surgery is another strategy to improve the
postoperative outcomes of CEA. Our data support the use
of statin and diuretic therapy in patients referred for surgery
with moderate to high-grade carotid stenosis for the pre-
vention of symptomatic carotid disease. The validity of
these findings, however, is limited by the retrospective
design of the study and potential confounders. The area
under the ROC curve results suggest that our final model
did not account for all variables associated with symptom-
atic carotid disease. Moreover, the referral patterns for
patients with symptomatic and asymptomatic carotid dis-
ease differ, as can be seen by the higher rate of asymptom-
atic patients who underwent synchronous CABG with as-
sociated cardiovascular comorbidities. Although propensity
score adjustment is a rigorous method used in observational
studies to control for confounders associated with drug
dispersement, there still may be unmeasured confounders
that influence our results and did not make it in to the
propensity model.14,30 Statin and diuretic use may just be
markers of higher-quality medical care, although if this is
true, it is interesting that other common cardiovascular
medications were not found to be associated with a reduc-
tion in symptoms. In fact, our data suggest that other
medications, such as calcium channel blockers, might actu-
ally be associated with a higher incidence of symptomatic
disease. Another limitation of this study is that serum lipid
levels and/or blood pressure measurements were not ob-
tained and compared between symptomatic and asymp-
tomatic groups. Furthermore, the duration of statin and
diuretic therapy before CEA was unknown. However, lim-
ited use of and/or noncompliance with statin and diuretic
therapy would serve only to underestimate the beneficial
effects of these medications in our study. It has been
suggested by prospective randomized studies of medical
patients taking statins that patients need to take these medi-
cations for as much as 3 years to gain a stroke-reduction
benefit.11 Future prospective clinical trials will be helpful to
confirm this temporal relationship and determine the opti-
mal dosing regimen of these therapies in patients with
carotid stenosis to achieve maximum benefits both before
and after surgery.
CONCLUSIONS
Our data suggest that statins and diuretics are indepen-
dently associated with a reduction in cerebrovascular symp-
toms among patients presenting for CEA. Providing opti-
mal medical management before surgery may help to
reduce the incidence of adverse perioperative outcomes.
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